# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* SULLIVAN GREGORY M				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner								
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVENUE, SUITE 1608					3. Date of Earliest Transaction (Month/Day/Year) 08/17/2020						X Officer (give title below) Other (specify below) Chief Medical Officer							
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City) (State) (Zip)				ip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)		2. Transac Date (Month/D	Day/Year)	2A. Dee Execution any (Month/		ĺ	Cod (Inst		v	(A) or I	Prities Acq Disposed (c, 4 and 5) (A) or (t (D)	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ollowing (s)	Ownership Form: Direct (D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$0.001		08/17/2	2020				]	P	20,000 A \$ 1.0		\$ 1.03	21,405			)			
Reminder:	Report on a s	separate line fo		able II - D	<b>)</b> erivat	ive Sec	uriti	es Ac	quire	Perso conta the fo	ons whained ir	o respon this for plays a	rm are curre	not requesting ntly valid		ormation pond unles	s	1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Year) Execution	Deemed ecution Date	e, if T	g, puts, calls, warrants, of  4.  5.  Transaction of Code of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ative ities ired resed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Ame Und Secu	itle and ount of erlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivati Security Direct ( or Indire	Beneficia Ownersh (Instr. 4)		
						Code	V	(A)	(D)	Date Exerc		Expiration Date	n Title	Amount or Number of Shares				

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SULLIVAN GREGORY M C/O TONIX PHARMACEUTICALS HOLDINGS CORP 509 MADISON AVENUE, SUITE 1608 NEW YORK, NY 10022			Chief Medical Officer			

## Signatures

/s/ Gregory M. Sullivan	08/19/2020
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.